Harilal Patel

667 total citations
46 papers, 512 citations indexed

About

Harilal Patel is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Harilal Patel has authored 46 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Oncology and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Harilal Patel's work include Neuropeptides and Animal Physiology (7 papers), Peroxisome Proliferator-Activated Receptors (6 papers) and Diabetes Treatment and Management (6 papers). Harilal Patel is often cited by papers focused on Neuropeptides and Animal Physiology (7 papers), Peroxisome Proliferator-Activated Receptors (6 papers) and Diabetes Treatment and Management (6 papers). Harilal Patel collaborates with scholars based in India, Switzerland and Australia. Harilal Patel's co-authors include Mukul R. Jain, Kevinkumar Kansagra, Nuggehally R. Srinivas, Rajendrakumar H. Jani, Dhruvanshu Parmar, Pankaj Patel, K Sairam, Ranjit C. Desai, Farheen Shaikh and Suresh Giri and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain Research and British Journal of Pharmacology.

In The Last Decade

Harilal Patel

44 papers receiving 495 citations

Peers

Countries citing papers authored by Harilal Patel

Since Specialization

Citations

This map shows the geographic impact of Harilal Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harilal Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harilal Patel more than expected).

Fields of papers citing papers by Harilal Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harilal Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harilal Patel. The network helps show where Harilal Patel may publish in the future.

Co-authorship network of co-authors of Harilal Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Harilal Patel. A scholar is included among the top collaborators of Harilal Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harilal Patel. Harilal Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia 2024 ·SHILAP Revista de lepidopterología ·Amit Joharapurkar, Vrajesh B. Pandya, Harilal Patel, Mukul Jain, Ranjit C. Desai	3
2	Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment 2024 ·Clinical Pharmacology & Therapeutics ·Raj Vuppalanchi, (unknown), (unknown), Farheen Shaikh, (unknown), Harilal Patel, (unknown)	4
3	Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment 2023 ·Clinical Pharmacology in Drug Development ·Eric Lawitz, Dhruvanshu Parmar, (unknown), Farheen Shaikh, Harilal Patel, Helen E. Hayes, (unknown)	2
4	Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants 2023 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Kevinkumar Kansagra, (unknown), (unknown), (unknown), (unknown), (unknown), Harilal Patel, Dhruvanshu Parmar	1
5	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes 2023 ·Clinical Pharmacology in Drug Development ·Pravin Hissaria, Kevinkumar Kansagra, (unknown), (unknown), (unknown), Harilal Patel, (unknown)	18
6	Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia 2022 ·European Journal of Drug Metabolism and Pharmacokinetics ·Harilal Patel, (unknown), (unknown), (unknown), (unknown), Hiren Patel, Vrajesh B. Pandya, Ranjit C. Desai, Mukul R. Jain	7
7	Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes 2021 ·Bioorganic & Medicinal Chemistry ·Suresh Pola, Shailesh R. Shah, (unknown), (unknown), (unknown), (unknown), (unknown), Debdutta Bandyopadhyay, Akshyaya Rath, Suresh Giri, (unknown), Ramchandra Ranvir, Sugantha Sundar, Harilal Patel, Jeevan Kumar, Mukul R. Jain	12
8	Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist 2021 ·Journal of Chromatography B ·(unknown), (unknown), (unknown), (unknown), Harilal Patel, Mukul R. Jain, (unknown), Dhruvanshu Parmar, Pankaj Patel	1
9	Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors 2020 ·Bioorganic Chemistry ·Rajesh Bahekar, (unknown), Shubhangi S. Soman, (unknown), Dipam Patel, (unknown), (unknown), (unknown), (unknown), Jeevan Kumar, (unknown), Harilal Patel, (unknown), Abhijit Chatterjee, (unknown), (unknown), (unknown), Debdutta Bandyopadhyay, Ranjit C. Desai	4
10	Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study 2019 ·American Journal of Nephrology ·Dhruvanshu Parmar, Kevinkumar Kansagra, Jatin Patel, (unknown), (unknown), (unknown), Nirav Patel, (unknown), Farheen Shaikh, Harilal Patel, (unknown)	55
11	Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1 2018 ·Cancer Chemotherapy and Pharmacology ·Mukul R. Jain, (unknown), (unknown), Abhijit Chatterjee, (unknown), Dinesh Kumar Patel, (unknown), (unknown), B. K. Srivastava, (unknown), (unknown), (unknown), Harilal Patel, (unknown), (unknown), (unknown), Nuggehally R. Srinivas, Pankaj Patel, Ranjit C. Desai	6
12	Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension 2018 ·Xenobiotica ·Harilal Patel, (unknown), (unknown), (unknown), (unknown), Alex George, (unknown), Nuggehally R. Srinivas	4
13	One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan 2017 ·European Journal of Pharmaceutical Sciences ·Harilal Patel, (unknown), (unknown), Shailesh Shah, (unknown), Bhavesh C. Variya, (unknown), Dipesh Baradia, (unknown), (unknown), Nuggehally R. Srinivas	0
14	Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives 2016 ·European Journal of Drug Metabolism and Pharmacokinetics ·Harilal Patel, (unknown), Nuggehally R. Srinivas	2
15	Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects 2013 ·Clinical Drug Investigation ·Rajendrakumar H. Jani, Kevinkumar Kansagra, Mukul R. Jain, Harilal Patel	49
16	Synthesis and structure–activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element 2012 ·European Journal of Medicinal Chemistry ·Vrajesh B. Pandya, Mukul R. Jain, Ganes Chakrabarti, Hitesh Soni, (unknown), (unknown), Jigar S. Patel, (unknown), (unknown), Nirav Joshi, Akshyaya Rath, (unknown), (unknown), Haresh Ajani, Jeevan Kumar, K Sairam, Harilal Patel, Pankaj Patel	38
17	Discovery of inhibitors of plasminogen activator inhibitor-1: Structure–activity study of 5-nitro-2-phenoxybenzoic acid derivatives 2011 ·Bioorganic & Medicinal Chemistry Letters ·Vrajesh B. Pandya, Mukul Jain, Ganes Chakrabarti, Hitesh Soni, (unknown), (unknown), Jigar S. Patel, (unknown), Nirav Joshi, Akshyaya Rath, (unknown), (unknown), K Sairam, Harilal Patel, Pankaj Patel	10
18	Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Shailesh R. Shah, (unknown), (unknown), (unknown), Suresh Pola, (unknown), Priyanka Priyadarshini, (unknown), (unknown), (unknown), K Sairam, Suresh Giri, (unknown), Harilal Patel, (unknown), Hiren Patel, Mukul Jain, Pankaj Patel, Rajesh Bahekar	7
19	Design and synthesis of novel oxazole containing 1,3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists 2008 ·Bioorganic & Medicinal Chemistry ·(unknown), Mukul R. Jain, Shailesh R. Shah, (unknown), (unknown), Ashish Goel, (unknown), Suresh Giri, Harilal Patel, Pankaj Patel	15
20	Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Mukul R. Jain, Shailesh R. Shah, (unknown), (unknown), (unknown), (unknown), Pravin Patil, (unknown), Suresh Giri, Ashish Goel, (unknown), Harilal Patel, Pankaj Patel	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact